For research use only. Not for therapeutic Use.
Seratrodast (Cat No.:I000479) is a potent and selective antagonist of the thromboxane A2 receptor (TP). As a TP antagonist, seratrodast blocks the binding of thromboxane A2 to its receptor, thereby inhibiting its signaling pathway. Thromboxane A2 is a potent vasoconstrictor and platelet aggregator, and its activation has been implicated in various cardiovascular and inflammatory conditions. By inhibiting the TP receptor, seratrodast has the potential to mitigate the effects of thromboxane A2, leading to vasodilation and antiplatelet activity.
| Catalog Number | I000479 |
| CAS Number | 112665-43-7 |
| Synonyms | ζ-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-benzeneheptanoic acid |
| Molecular Formula | C22H26O4 |
| Purity | ≥95% |
| Target | Prostaglandin Receptor |
| Solubility | DMSO:12 mg/ml ； ethanol:10 mg/ml |
| Storage | Store at -20°C |
| IUPAC Name | 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid |
| InChI | InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24) |
| InChIKey | ZBVKEHDGYSLCCC-UHFFFAOYSA-N |
| SMILES | CC1=C(C(=O)C(=C(C1=O)C)C(CCCCCC(=O)O)C2=CC=CC=C2)C |
| Reference | </br>1:Crystal structure of 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxo-cyclo-hexa-1,4-dien-1-yl)hepta-noate 1,3-dihy-droxy-2-(hy-droxy-meth-yl)propan-2-aminium monohydrate: a new solid form of seratrodast. Lou B.Acta Crystallogr Sect E Struct Rep Online. 2014 Sep 20;70(Pt 10):228-30. doi: 10.1107/S1600536814020625. eCollection 2014 Oct 1. PMID: 25484659 Free PMC Article</br>2:Indium-catalyzed synthesis of keto esters from cyclic 1,3-diketones and alcohols and application to the synthesis of seratrodast. Kuninobu Y, Kawata A, Noborio T, Yamamoto S, Matsuki T, Takata K, Takai K.Chem Asian J. 2010 Apr 1;5(4):941-5. doi: 10.1002/asia.200900553. PMID: 20235270 </br>3:Isolation and structure elucidation of the major photodegradation products of seratrodast. Xu J, Zhang Y, Hu Y.J Pharm Biomed Anal. 2008 Sep 10;48(1):78-84. doi: 10.1016/j.jpba.2008.05.002. Epub 2008 May 13. PMID: 18562149 </br>4:[Design, synthesis and antiasthmatic activities of NO-donating seratrodast derivatives]. Zhang ZG, Zhang YH, Ji H, Qiu SG, Feng XC.Yao Xue Xue Bao. 2004 Sep;39(9):705-10. Chinese. PMID: 15606018 </br>5:The effect of seratrodast on eosinophil cationic protein and symptoms in asthmatics. Fukuoka T, Miyake S, Umino T, Inase N, Tojo N, Yoshizawa Y.J Asthma. 2003 May;40(3):257-64. PMID: 12807169 </br>6:A kinetic and thermodynamic study of seratrodast polymorphic transition by isothermal microcalorimetry. Urakami K, Beezer AE.Int J Pharm. 2003 May 12;257(1-2):265-71. PMID: 12711181 </br>7:Study on the usefulness of seratrodast in the treatment of chronic pulmonary emphysema. Horiguchi T, Tachikawa S, Kondo R, Shiga M, Hirose M, Fukumoto K.Arzneimittelforschung. 2002;52(10):764-8. PMID: 12442639 </br>8:[Correlation between the clinical effects of Seratrodast and the level of 11-dehydrothromboxane B2 in urine/sputum in bronchial asthma patients]. Muramatsu H, Kotajima R, Sato T.Arerugi. 2001 Jun;50(6):540-6. Japanese. PMID: 11517517 </br>9:Antagonism of the TXA2 receptor by seratrodast: a structural approach. Wouters J, Durant F, Masereel B.Bioorg Med Chem Lett. 1999 Oct 4;9(19):2867-70. PMID: 10522708 </br>10:[Thromboxane A2 antagonist–discovery of seratrodast]. Terao S, Shiraishi M, Matsumoto T, Ashida Y.Yakugaku Zasshi. 1999 May;119(5):377-90. Review. Japanese. PMID: 10375998 |
